PRF1 and acute myeloid leukemia: Through Bcl‐2 inhibition, venetoclax alleviated the resistance of AML cells to granzyme B/perforin‐mediated killing, amplifying the anti‐leukaemic effects of ICT01‐activated γ9δ2 T cells, NK cells, and CD8+ T cells.